Financial Performance - The group recorded revenue of approximately SGD 10.4 million for the nine months ended September 30, 2021, an increase of about 7.9% compared to SGD 9.6 million for the same period last year[4]. - Gross profit for the period was approximately SGD 6.9 million, slightly down by about 0.9% from SGD 6.8 million in the previous year[4]. - The group reported a net loss after tax of approximately SGD 0.9 million, compared to a net profit of SGD 0.3 million in the same period last year[5]. - The group reported a basic loss per share of SGD (0.17) for the nine months ended September 30, 2021, compared to a profit of SGD 0.06 for the same period in 2020[22]. - The group’s total revenue for the three months ended September 30, 2021, was SGD 3.0 million, a decrease from SGD 4.1 million in the same period in 2020[17]. - The group’s medical examination service revenue for the three months ended September 30, 2021, was SGD 0.7 million, down from SGD 1.0 million in the same period in 2020[17]. Expenses and Costs - Employee benefits expenses increased by approximately SGD 0.6 million or 13.8% to SGD 4.6 million, attributed to efforts to retain and attract staff[5]. - Depreciation of property, plant, and equipment rose by approximately 94.6% to about SGD 1.4 million, driven by new treatment centers[5]. - Other operating expenses increased by approximately SGD 0.9 million or 60.1% to SGD 2.4 million, due to marketing and promotional activities[5]. - Gross profit rose to approximately SGD 6.9 million, while the gross profit margin decreased from about 70.7% to approximately 66.1% due to increased medical supplies and professional costs[32]. - Depreciation expenses rose by approximately SGD 0.7 million or 94.6% to about SGD 1.4 million, mainly due to the establishment of new treatment centers[34]. Equity and Capital - Total equity as of September 30, 2021, was approximately SGD 15.9 million, reflecting changes in retained earnings and currency translation reserves[10]. - Cash and cash equivalents amounted to approximately SGD 13.7 million as of September 30, 2021, an increase from SGD 13.0 million as of December 31, 2020[41]. - The capital debt ratio was approximately 13.4% as of September 30, 2021, down from 20.8% as of December 31, 2020[42]. - The group completed a placement of 104 million shares, raising approximately HKD 20 million, with 60% allocated for business expansion and 40% for working capital[45]. Corporate Governance - The company has adopted corporate governance standards in compliance with GEM listing rules, ensuring a minimum number of independent non-executive directors[53]. - The company has established a code of conduct for directors' securities transactions, ensuring compliance with GEM listing rules[55]. - The company is committed to enhancing corporate governance practices regularly[53]. - The audit committee, consisting of three independent non-executive directors, reviewed the unaudited consolidated financial statements and confirmed compliance with applicable accounting standards and regulations[69]. Business Operations - The group has nine DTAP clinics and one S Aesthetics clinic operational as of the report date, with plans to explore additional primary care business opportunities[28]. - The group aims to enhance its brand image and connect with existing and new customers through various marketing initiatives[5]. - The Singapore government has implemented community safety measures in response to the rising COVID-19 cases, which may impact the healthcare sector's operations[28]. - The group completed the acquisition of six clinics on April 1, 2020, as part of its internal restructuring[13]. Shareholder Information - As of September 30, 2021, Dr. Chen held 350,000,000 shares, representing 56.09% of the company's issued shares[60]. - Cher Sen Holdings Limited, controlled by Dr. Chen, holds all issued shares, making him the beneficial owner[61]. - Liu Hewen owns 52,630,000 shares, accounting for 8.43% of the total issued shares[64]. - The company has not granted or agreed to grant any options under the share option plan since its adoption[58]. - The share option plan allows for a maximum of 10% of the issued share capital to be granted as options[58]. Miscellaneous - The company has not disclosed any new product developments or market expansions in the report[68]. - There were no significant investments or acquisitions during the period[47]. - There were no significant events affecting the company after September 30, 2021, up to the report date[52]. - The company did not redeem any of its listed securities during the reporting period[67]. - The company has not purchased or sold any of its listed securities during the reporting period[67]. - The compliance advisor has no interests in the company's securities as of September 30, 2021[66]. - No directors or controlling shareholders have interests in any competing businesses during the reporting period[65]. - The company’s financial reporting process and internal controls are monitored by the audit committee[69].
REPUBLIC HC(08357) - 2021 Q3 - 季度财报